3 citations
,
August 2022 in “International Journal of Molecular Sciences” This review discusses the increased incidence of hair loss and telogen effluvium among COVID-19 patients and evaluates existing evidence for regenerative treatments like PRP and HFSCs, finding limited published data.
12 citations
,
July 2022 in “Journal of Cosmetic Dermatology” This review identifies existing evidence on the connection between COVID-19 and hair loss, suggesting that hair loss associated with COVID-19 may primarily involve telogen effluvium and be reversible.
4 citations
,
June 2022 in “Indian Dermatology Online Journal” This review discusses post-COVID hair loss, attributing it to potential pathogenic factors like cytokines and viral effects, and suggests that full recovery without specific treatment is expected.
3 citations
,
June 2022 in “Journal of the European Academy of Dermatology and Venereology” This study describes the presence of SARS-CoV-2 in hair follicles from a patient with early-onset post-COVID hair loss, suggesting a potential direct impact of the virus on hair physiology.
7 citations
,
May 2022 in “The Journal of Dermatology” This narrative review found that post-COVID-19 hair loss, particularly telogen effluvium, poses a significant mental and social burden, with minoxidil potentially aiding recovery, although more clinical research is needed to confirm its effectiveness.
25 citations
,
February 2022 in “JAAD International” This review analyzed data on alopecia types associated with COVID-19, suggesting androgenetic alopecia may be a risk factor for severe COVID-19, while telogen effluvium often follows infection and alopecia areata tends to relapse in those with preexisting disease.
25 citations
,
December 2021 in “Journal of Medical Virology” This systematic review reports that acute telogen effluvium may occur as a stress-induced hair loss following COVID-19 recovery, with most patients experiencing hair regrowth over time.
22 citations
,
October 2021 in “Dermatologic Therapy” This study found that approximately one-quarter of post-COVID-19 patients experienced telogen effluvium, with a higher incidence among women, hospitalized patients, and those with hypertension or respiratory symptoms.
1250 citations
,
August 2021 in “Scientific Reports” In this study, researchers estimated that 80% of patients infected with SARS-CoV-2 experienced at least one long-term symptom, with fatigue being the most common.
39 citations
,
August 2021 in “JAAD International” This study found that telogen effluvium and trichodynia are common in patients after COVID-19, and their severity may be influenced by the severity of the COVID-19 infection.
32 citations
,
July 2021 in “Journal of The American Academy of Dermatology” This study found that acute telogen effluvium after COVID-19 typically began about 1.5 months post-infection and resolved sooner than typical cases, with most resolving in under two months.
4 citations
,
March 2021 in “International Journal of Dermatology” COVID-19 and related stress may increase hair loss known as Telogen effluvium.
23 citations
,
January 2021 in “Journal of Dermatological Science” This review describes the diagnosis and management challenges of telogen effluvium, a type of hair loss triggered by physiological stress, and summarizes current understanding of its mechanisms and treatments while recommending future research directions.
28 citations
,
January 2021 in “Skin appendage disorders” This study observed that telogen effluvium, or acute hair loss, often occurs 1 to 3 months after SARS-CoV-2 infection, earlier than classic telogen effluvium.
51 citations
,
November 2020 in “Journal of the European Academy of Dermatology and Venereology” This article discusses SARS-CoV-2-induced telogen effluvium in a multicentric study and reports no new clinical results.
24 citations
,
August 2020 in “AJGP” A woman's sudden hair loss was linked to her previous COVID-19 infection.
43 citations
,
July 2020 in “Dermatologic Therapy” This study observed a significant increase in certain dermatologic conditions a month and two months after the onset of the COVID-19 pandemic in Turkey, which may suggest a link with asymptomatic COVID-19 infection.
40 citations
,
May 2020 in “Cureus” This review discusses the causes, diagnosis, and treatment of telogen effluvium and reports no new clinical findings; the authors underscore the importance of identifying and eliminating causative factors.
56 citations
,
August 2019 in “Clinical, Cosmetic and Investigational Dermatology” This essay discusses telogen effluvium, the issues surrounding its diagnosis and differentiation from other forms of hair loss, and emphasizes the need for empathetic patient care; it reports no new clinical findings.
26 citations
,
December 2015 in “International Journal of Dermatology” This abstract reviews the symptom of trichodynia, a painful scalp sensation linked to hair loss, and highlights its potential connection to inflammation but reports no new research findings.
70 citations
,
January 2015 in “Journal of Clinical and Diagnostic Research” This review discusses the various triggers and diagnostic challenges in determining the cause of telogen effluvium-related hair loss, without providing new clinical results.
67 citations
,
January 2013 in “Indian Journal of Dermatology, Venereology and Leprology” This review discusses telogen effluvium, a common type of hair loss, focusing on differentiation from other conditions and potential causes, but presents no new research findings.
173 citations
,
September 2011 in “Journal of Investigative Dermatology” IL-6 contributes to hair loss by shortening the growth phase and causing hair follicles to regress.
26 citations
,
August 2006 in “Journal of Clinical Pharmacy and Therapeutics” This study reported that enoxaparin may cause alopecia in patients treated for cerebral venous thrombosis, with hair growth resuming naturally after the treatment ended.
144 citations
,
July 2002 in “Clinical and Experimental Dermatology” This article reviews the concept of telogen effluvium and emphasizes the importance of identifying triggers and using diagnostic investigations to determine the cause of hair loss, without reporting new results.
147 citations
,
April 1994 in “Drug Safety” Some drugs can cause hair loss or increase hair growth, but these effects are usually reversible when the drug is stopped.
214 citations
,
March 1993 in “Archives of Dermatology” This article proposes five different mechanisms for telogen effluvium, supported by clinical findings, based on changes in different phases of the hair cycle.